|

Tazemetostat Hydrobromide Clinical Trials

1 actively recruiting trial across 1 location

Also known as: EPZ-6438 Monohydrobromide, TAZVERIK, Tazemetostat Monohydrobromide

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Recurrent Lung Small Cell Carcinoma1
  • Recurrent Extensive Stage Lung Small Cell Carcinoma1
  • Platinum-Sensitive Lung Small Cell Carcinoma1
  • Platinum-Resistant Lung Small Cell Carcinoma1
  • Limited Stage Lung Small Cell Carcinoma1

Los Angeles, California1 trial

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Keck Medicine of USC Koreatown

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.